B. Riley Securities Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $179
Author: Benzinga Newsdesk | October 01, 2025 09:33am
B. Riley Securities analyst Madison El-Saadi initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and announces Price Target of $179.